Eli Lilly Reports Results of Cyramza (ramucirumab) in P-III REACH 2 study for 2L AFP-High HCC, Published in The Lancet

 Eli Lilly Reports Results of Cyramza (ramucirumab) in P-III REACH 2 study for 2L AFP-High HCC, Published in The Lancet

Eli Lilly Reports Results of Cyramza (ramucirumab) in P-III REACH 2 study for 2L AFP-High HCC, Published in The Lancet

Shots:

  • The P-III REACH 2 study involves assessing of Cyramza + best supportive care (BSC) vs PBO + BSC in 292 patients with high alpha fetoprotein (AFP-High) >400ng/ml (HCC), who were intolerant to, or who had disease progression while on or following treatment with sorafenib
  • P-III REACH 2 study results: 1EP@ mOS (8.5 vs 7.3mos); 2EP@ mPFS (2.8 vs 1.6mos); ORR (4.6% vs 1.1%); Disease Control Rate (ORR + stable disease) (59.9% vs 38.9%); pooled results: OS (8.1 vs 5.0mos), Presented in ASCO 2018
  • Cyramza is a VEGF Receptor 2 antagonist serving as an antiangiogenic therapy, indicated as monothx or in combination with paclitaxel & docetaxel for metastatic gastric & metastatic NSCLC respectively. The company has filled its BLA in the US, EU & Japan

Click here to read full press release/ article | Ref: Eli Lilly | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post